Angiodynamics (ANGO) EBITDA (2016 - 2025)
Historic EBITDA for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to -$6.1 million.
- Angiodynamics' EBITDA rose 4479.0% to -$6.1 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$32.5 million, marking a year-over-year increase of 8635.73%. This contributed to the annual value of -$40.0 million for FY2025, which is 7923.77% up from last year.
- Per Angiodynamics' latest filing, its EBITDA stood at -$6.1 million for Q4 2025, which was up 4479.0% from -$10.7 million recorded in Q3 2025.
- In the past 5 years, Angiodynamics' EBITDA registered a high of $35.0 million during Q3 2023, and its lowest value of -$199.9 million during Q1 2024.
- In the last 5 years, Angiodynamics' EBITDA had a median value of -$9.5 million in 2023 and averaged -$17.7 million.
- Per our database at Business Quant, Angiodynamics' EBITDA soared by 36336.37% in 2023 and then tumbled by 213897.85% in 2024.
- Over the past 5 years, Angiodynamics' EBITDA (Quarter) stood at -$8.7 million in 2021, then rose by 6.5% to -$8.1 million in 2022, then tumbled by 61.68% to -$13.1 million in 2023, then increased by 15.44% to -$11.1 million in 2024, then surged by 44.79% to -$6.1 million in 2025.
- Its last three reported values are -$6.1 million in Q4 2025, -$10.7 million for Q3 2025, and -$5.8 million during Q2 2025.